The IAPAM has enhanced its globally-respected website (IAPAM.com) with new content on the newest player in the injectables arena: Xeomin.
Las Vegas, Nevada, USA – March 12, 2013 — The IAPAM has enhanced its globally-respected website (http://www.iapam.com) with new content on the newest player in the injectables arena: Xeomin. As part of the IAPAM’s commitment to keeping physicians and patient informed, the Aesthetic Resources pages provide consumers and doctors with treatment-focused content and timely intelligence on the aesthetic medicine industry’s leading products and procedures.
After a 10 month injunction, Xeomin is again being launched in the US as a treatment of glabellar lines. Therefore, the IAPAM announces the launch of a NEW Aesthetic Resources Page on Xeomin (http://iapam.com/xeomin-incobotulinumtoxina). This NEW content provides an overview of this new and recently approved neurotoxin, and is aimed to educate physicians and patients alike on the pros and cons of this new competitor to botox.
Providing physicians, their staff and consumers with DYNAMIC CONTENT is the mission of the International Association for Physicians in Aesthetic Medicine (IAPAM). Comprised of physicians, business experts, researchers and communications specialists, the IAPAM Team is driven to ensure that its website, (IAPAM.com), is the best one-stop ‘window’ for both physicians new to aesthetic medicine, as well as seasoned professionals and patients. IAPAM.com is dedicated to keeping physicians and patients up to date with ever-changing, relevant information on current clinical treatments, costs benefits, business improvements, horizon technologies and global trends in the aesthetic medical arena.
The new page on Xeomin (http://iapam.com/xeomin-incobotulinumtoxina), offers an Executive Summary including intelligence such as:
– The main difference between Xeomin and Botox or Dysport, is that Xeomin contains just one ingredient: botulinum toxin A.
– Xeomin is a “naked injectable,” meaning that it does not contain any additives. A benefit of a pure-form injectable is that the human body is less likely to become resistant to it.
– Xeomin is the only one of the three (Xeomin, Botox and Dysport) that does not need to be refrigerated before use, and much much more.
Come and use the ever-expanding content on the IAPAM’s Website. Also, follow the IAPAM’s Executive Director, Jeff Russell, as he provides timely advice to physicians in his weekly blog (http://iapam.com/category/iapam-blog) and subscribe to our Aesthetic Medicine News RSS Feed (http://feeds.feedburner.com/AestheticMedicineNews) to receive breaking news about aesthetic medicine advances. If you have any questions regarding aesthetic medical treatments, new technologies, new products, or future trends, please contact the IAPAM at 1-800-219-5108 or visit http://www.iapam.com.
Botox is a trademark of Allergan, Inc. Dysport is a trademark of Medicis, Inc. Xeomin is a trademark of Merz Pharmaceuticals LLC.
About the International Association for Physicians in Aesthetic Medicine (IAPAM)
The International Association for Physicians in Aesthetic Medicine is a voluntary global association of physicians and supporters, which sets standards for the aesthetic medical profession worldwide. The goal of the association is to offer education, ethical standards, credentialing, and member benefits to members around the globe. IAPAM membership is open to all licensed medical doctors (MDs), doctors of osteopathic medicine (DOs), physicians assistants (PAs) and nurse practitioners (NPs). The IAPAM offers aesthetic medicine and hCG medical weight management programs, including: Botox training, medical aesthetic training, laser training, physician hCG training, and aesthetic practice business training. Additional information about the association can be accessed through the IAPAM’s website (http://www.iapam.com) or by contacting:
Jeff Russell, Executive-Director
International Association for Physicians in Aesthetic Medicine (IAPAM)
1-800-219-5108 x704
